US FDA extends review of Novo Nordisk's hemophilia drug over facility issues - Reuters
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOUDlXRmJMY2FnM1FQSzF0WHVLaU9TUU11NGhkN0wzREowT3FpRF94V25CX0xEN3dZZjZvcTg4dkhxUEJOUklGaUpyVy1RMGhiSHE4d2gyRVhXWUlqbHo1ODVhQnFSMkR1Z3J2RFF2NU5tbnF0aTA4Uk5uaGZLZTdKcG5DUWpleTBFbzNaTGdWbEpRdXhhQ1ZLODFjVHMtYWJraEFZWjhGcWJtSlRXX1dZY1BHUm15Q3BfTWJub01zdkd2U1E?oc=5" target="_blank">US FDA extends review of Novo Nordisk's hemophilia drug over facility issues</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Novo Nordisk to license experimental GLP-1 pill from China's Hengrui - Reuters
Novo Nordisk to license experimental GLP-1 pill from China's Hengrui Reuters
September 29, 2026 at 04:47 AMUS FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie's drug for Parkinson's disease reuters.com
September 25, 2026 at 10:57 PMPatients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study - Reuters
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study Reuters
September 30, 2026 at 09:57 AMLilly's experimental drug cuts weight by 21% in diabetes trial - reuters.com
Lilly's experimental drug cuts weight by 21% in diabetes trial reuters.com
September 29, 2026 at 10:15 PMNovo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - reuters.com
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro reuters.com
September 29, 2026 at 09:49 PMBayer to invest $2.2 billion in new US pharma site - Reuters
Bayer to invest $2.2 billion in new US pharma site Reuters
October 2, 2026 at 07:19 PM